Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022

touchCONGRESS for touchONCOLOGY Listen to urological cancer expert Prof. Axel Merseburger (Germany) review key data presented at ESMO 2022 exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer.  He then offers his views on the potential impact of these data on clinical practice, alongside expert insights from Dr Bradley McGregor (USA) and Prof. Andrea Necchi (Italy).    OVERVIEW Data Review with Prof. Merseburger (00:00) Expert interviews with Prof. Merseburger, Dr McGregor and Prof. Necchi answering the questions below INTERVIEW QUESTIONS Based on data recently presented at ESMO 2022, how do you think new and emerging immunotherapy agents and targeted treatments for patients with bladder cancer will impact the treatment landscape? (31:45) How can key learnings from ESMO 2022 be integrated into clinical practice when choosing between available regimens? (37:42) How is our understanding of the role of PD-L1 as a biomarker in bladder cancer evolving in light of recent data, and what are the possible implications for clinical practice? (44:35) What unmet needs remain surrounding biomarkers beyond PD-L1 in bladder cancer, and what are the prospects for biomarker-driven individualized treatment decisions in future? (51:14) This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical educational grant from Seagen Inc. and Astellas Pharma Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/bladder-cancer-esmo2022-touchcongress/https://touchoncologyime.org/bladder-cancer-esmo2022-touchcongress/